ES2263182T3 - Composicion adecuada para el tratamiento de laminitis equina. - Google Patents

Composicion adecuada para el tratamiento de laminitis equina.

Info

Publication number
ES2263182T3
ES2263182T3 ES97948262T ES97948262T ES2263182T3 ES 2263182 T3 ES2263182 T3 ES 2263182T3 ES 97948262 T ES97948262 T ES 97948262T ES 97948262 T ES97948262 T ES 97948262T ES 2263182 T3 ES2263182 T3 ES 2263182T3
Authority
ES
Spain
Prior art keywords
composition
arg
weight
equine
donor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97948262T
Other languages
English (en)
Spanish (es)
Inventor
Meri Charmyne Russell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DMK Pharmaceuticals Corp
Original Assignee
Cellegy Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellegy Pharmaceuticals Inc filed Critical Cellegy Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2263182T3 publication Critical patent/ES2263182T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A61K9/0017—Non-human animal skin, e.g. pour-on, spot-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES97948262T 1996-11-19 1997-11-17 Composicion adecuada para el tratamiento de laminitis equina. Expired - Lifetime ES2263182T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/752,415 US5891472A (en) 1996-11-19 1996-11-19 Treatment of equine laminitis
US752415 1996-11-19

Publications (1)

Publication Number Publication Date
ES2263182T3 true ES2263182T3 (es) 2006-12-01

Family

ID=25026227

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97948262T Expired - Lifetime ES2263182T3 (es) 1996-11-19 1997-11-17 Composicion adecuada para el tratamiento de laminitis equina.

Country Status (10)

Country Link
US (3) US5891472A (https=)
EP (1) EP0946147B1 (https=)
JP (1) JP2001509136A (https=)
AT (1) ATE326948T1 (https=)
AU (1) AU5435998A (https=)
BR (1) BR9714573A (https=)
CA (1) CA2273183A1 (https=)
DE (1) DE69735949T2 (https=)
ES (1) ES2263182T3 (https=)
WO (1) WO1998022090A1 (https=)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
US6479074B2 (en) 1996-10-24 2002-11-12 Pharmaceutical Applications Associates Llc Methods and transdermal compositions for pain relief
US5891472A (en) * 1996-11-19 1999-04-06 Meri Charmyne Russell Treatment of equine laminitis
US7629384B2 (en) * 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
US7914814B2 (en) * 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
US6306383B1 (en) * 1998-09-16 2001-10-23 Wilson T Crandall Method for topical treatment of scars with protein kinase C inhibitors
MXPA00006196A (es) * 1998-10-23 2003-07-21 Idea Ag Metodo para desarrollar, evaluar y utilizar asociaciones de macromoleculas y agregados complejos para obtener mejores tasas de asociacion/desasociacion controlable y carga efectiva.
SI1031347T1 (en) 1999-01-27 2002-10-31 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
PT1031346E (pt) 1999-01-27 2002-09-30 Idea Ag Vacinacao nao invasiva atraves da pele
WO2001001962A1 (en) * 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
KR20030065463A (ko) * 2000-08-11 2003-08-06 데이비드 알. 휘트록 질소 산화물 및 질소 산화물 전구체의 생산을 증가시키기위한 암모니아 산화 박테리아를 포함하는 조성물 및 이를이용하는 방법
JP2002136025A (ja) * 2000-10-26 2002-05-10 Mitsubishi Electric Corp 電磁機器
US6780849B2 (en) * 2000-12-21 2004-08-24 Scimed Life Systems, Inc. Lipid-based nitric oxide donors
US6833139B1 (en) * 2002-01-09 2004-12-21 Ferndale Laboratories, Inc. Composition and method for the treatment of anorectal disorders
CN1308438C (zh) * 2002-01-11 2007-04-04 大卫·R·怀特洛克 含有氨氧化细菌的化合物以及使用的方法
US20040018237A1 (en) 2002-05-31 2004-01-29 Perricone Nicholas V. Topical drug delivery using phosphatidylcholine
US20040092819A1 (en) * 2002-08-16 2004-05-13 Hmt High Medical Technologies Ag Method for treating laminitis in horses, ponies and other equines with acoustic waves
US20040105881A1 (en) * 2002-10-11 2004-06-03 Gregor Cevc Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
US6936273B2 (en) * 2002-12-20 2005-08-30 Idexx Laboratories, Inc. Liposomal analgesic formulation and use
EP1667646A4 (en) * 2003-09-26 2007-07-04 David R Whitlock METHOD FOR USE OF AMMONIA-OXIDATING BACTERIA
EP1732577B1 (en) * 2004-02-23 2013-04-10 Strategic Science & Technologies, LLC Topical delivery of l-arginine to improve body and skin appearance
US20090105336A1 (en) * 2004-04-19 2009-04-23 Strategic Science & Technologies, Llc Beneficial Effects of Increasing Local Blood Flow
US9050365B2 (en) * 2004-04-19 2015-06-09 Strategic Science & Technologies, Llc Transdermal delivery of beneficial substances effected by a hostile biophysical environment
US20110028548A1 (en) * 2004-04-19 2011-02-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US20060078580A1 (en) * 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US7740875B2 (en) * 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
CA2584475A1 (en) * 2004-11-12 2006-05-18 Idea Ag Extended surface aggregates in the treatment of skin conditions
US7731993B2 (en) * 2004-11-17 2010-06-08 Lindsey Berkson Composition for treating a dermal anomaly
JP2008520694A (ja) * 2004-11-17 2008-06-19 リンジー・バークソン 非治癒性及び治癒遅延性の創傷及び潰瘍の治癒を促進させる組成物及び方法
EP1888510A4 (en) 2005-05-27 2013-01-16 Univ North Carolina NITROGEN OXIDE-RELATED PARTICLES FOR NITROGEN OXIDE THERAPEUTICS AND BIOMEDICAL APPLICATIONS
US7744928B2 (en) * 2006-04-14 2010-06-29 Advanced Cardiovascular Systems, Inc. Methods and compositions for treatment of lesioned sites of body vessels
US7975699B2 (en) 2007-10-30 2011-07-12 The Invention Science Fund I, Llc Condoms configured to facilitate release of nitric oxide
US8221690B2 (en) 2007-10-30 2012-07-17 The Invention Science Fund I, Llc Systems and devices that utilize photolyzable nitric oxide donors
US7862598B2 (en) 2007-10-30 2011-01-04 The Invention Science Fund I, Llc Devices and systems that deliver nitric oxide
US8642093B2 (en) 2007-10-30 2014-02-04 The Invention Science Fund I, Llc Methods and systems for use of photolyzable nitric oxide donors
US20100292280A1 (en) * 2007-04-15 2010-11-18 Oron Zachar Anti-pyretic vasodilators
US8349262B2 (en) 2007-10-30 2013-01-08 The Invention Science Fund I, Llc Nitric oxide permeable housings
US8877508B2 (en) 2007-10-30 2014-11-04 The Invention Science Fund I, Llc Devices and systems that deliver nitric oxide
US8980332B2 (en) 2007-10-30 2015-03-17 The Invention Science Fund I, Llc Methods and systems for use of photolyzable nitric oxide donors
US7897399B2 (en) 2007-10-30 2011-03-01 The Invention Science Fund I, Llc Nitric oxide sensors and systems
US10080823B2 (en) 2007-10-30 2018-09-25 Gearbox Llc Substrates for nitric oxide releasing devices
EP2889028A1 (en) * 2008-06-24 2015-07-01 Intervet International B.V. Pharmaceutical transdermal compositions and method for treating inflammation in cattle
US20100227895A1 (en) * 2009-03-05 2010-09-09 Mpco- The Magic Powder Company Method for treating equine laminitis
WO2010151241A1 (en) 2009-06-24 2010-12-29 Strategic Science & Technologies, Llc Topical composition containing naproxen
US12138268B2 (en) 2009-06-24 2024-11-12 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
EP3045171A1 (en) * 2009-06-24 2016-07-20 Strategic Science & Technologies, LLC Topical composition
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
WO2011022652A1 (en) 2009-08-21 2011-02-24 Novan, Inc. Topical gels
BR112012003804B1 (pt) 2009-08-21 2019-02-19 Novan, Inc. Curativo para ferimentos, método para formar um curativo para ferimentos, e, kit de curativo para ferimento
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
CN103442723A (zh) 2010-12-29 2013-12-11 战略科学与技术有限责任公司 治疗变态反应和其它适应症的系统和方法
CN105920603B (zh) 2010-12-29 2022-02-11 战略科学与技术有限责任公司 勃起功能障碍和其它适应症的治疗
ES2695173T3 (es) 2011-02-28 2019-01-02 Novan Inc Partículas de sílice modificadas con S-nitrosotiol que liberan óxido nítrico y procedimientos de fabricación de las mismas
CN103547258B (zh) 2011-03-17 2017-10-20 特兰斯德梅尔生物工艺股份有限公司 局部一氧化氮系统及其使用方法
US8871256B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and systems for treatment of inflammatory diseases with nitric oxide
US8871259B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Techniques and systems for treatment of neuropathic pain and other indications
US8871258B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment and prevention of learning and memory disorders
US8871257B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Prevention and treatment of cardiovascular diseases using systems and methods for transdermal nitric oxide delivery
US8871262B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Compositions and methods for treatment of osteoporosis and other indications
US8871261B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Cancer treatments and compositions for use thereof
US8871254B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US8871255B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Treatment of skin and soft tissue infection with nitric oxide
US8871260B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Methods and compositions for muscular and neuromuscular diseases
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9295636B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US20140271731A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US20140271937A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US20140271938A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US20160058721A1 (en) 2013-04-01 2016-03-03 Daiichi Sankyo Company, Limited Formulation for treating equine inflammation
US10517817B2 (en) 2013-05-09 2019-12-31 Syk Technologies, Llc Deep topical systemic nitric oxide therapy apparatus and method
KR20210100224A (ko) 2014-04-15 2021-08-13 에이오바이오미 엘엘씨 암모니아-산화 니트로소모나스 유트로파 균주 d23
US11225640B2 (en) 2014-04-15 2022-01-18 Aobiome Llc Ammonia oxidizing bacteria for treatment of psoriasis
ES2968200T3 (es) 2016-01-27 2024-05-08 Syk Tech Llc Aparato y métodos de aplicación tópica de óxido nítrico
CN110225746A (zh) * 2016-11-09 2019-09-10 普罗维塔欧洲技术有限公司 用于治疗兽蹄感染的抗微生物制剂

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2440371A1 (fr) * 1978-10-31 1980-05-30 Fisons Ltd Nouveaux composes azotes heterocycliques, des compositions pharmaceutiques en contenant et des procedes pour les preparer
IE54286B1 (en) * 1983-01-18 1989-08-16 Elan Corp Plc Drug delivery device
CA1319886C (en) * 1987-02-03 1993-07-06 Alberto Ferro Mixed micelle solutions
CH681427A5 (https=) * 1987-07-01 1993-03-31 Zambon Spa
CH680223A5 (https=) * 1989-07-17 1992-07-15 Pier Luigi Prof Dr Luisi
DE4305881C1 (de) * 1993-02-26 1994-03-03 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit Wirkstoffen, welche Stichoxid-Quellen darstellen, Verfahren zu seiner Herstellung sowie seine Verwendung
ATE200026T1 (de) * 1993-08-28 2001-04-15 Univ Sheffield Behandlung von laminitis
GB2292520B (en) * 1994-08-25 1998-09-02 Univ Sheffield Transdermal dressings for animals
US5543430A (en) * 1994-10-05 1996-08-06 Kaesemeyer; W. H. Method and formulation of stimulating nitric oxide synthesis
US5891472A (en) * 1996-11-19 1999-04-06 Meri Charmyne Russell Treatment of equine laminitis

Also Published As

Publication number Publication date
ATE326948T1 (de) 2006-06-15
WO1998022090A1 (en) 1998-05-28
AU5435998A (en) 1998-06-10
EP0946147A4 (en) 2001-12-12
EP0946147A1 (en) 1999-10-06
US6045827A (en) 2000-04-04
CA2273183A1 (en) 1998-05-28
JP2001509136A (ja) 2001-07-10
EP0946147B1 (en) 2006-05-24
US6287601B1 (en) 2001-09-11
BR9714573A (pt) 2002-07-23
US5891472A (en) 1999-04-06
DE69735949T2 (de) 2007-01-04
DE69735949D1 (de) 2006-06-29

Similar Documents

Publication Publication Date Title
ES2263182T3 (es) Composicion adecuada para el tratamiento de laminitis equina.
ES2391914T3 (es) Formulación farmacéutica tópica
ES2607476T3 (es) Composición tópica que contiene ibuprofeno
EP0672422B1 (en) Antiinflammatory and analgesic transdermal gel containing Ketoprofen
ES2429443T3 (es) Suministro transdérmico de sustancias beneficiosas efectuado mediante un entorno de fuerza iónica elevada
ES3011984T3 (en) Treatment of erectile dysfunction
ES2330295B1 (es) Formulacion topica de ibuprofeno.
JPH05178764A (ja) 局所用あるいは経皮用製品におけるジブチルアジペートとイソプロピルミリステートの用途
CA2489188C (en) Transdermal absorption preparation
JP2013515020A (ja) 溶媒混合物およびビタミンｄ誘導体から成る医薬品組成物または類似体
Belgamwar et al. Pluronic lecithin organogel
CN109715138A (zh) 前列环素类似物制剂
ES2659940T3 (es) Composición veterinaria inyectable para animales pequeños
PT2197492E (pt) Novas composições à base de taxóides
ES2220787T3 (es) Composiciones antifungicas a base de cetoconazol, destinadas a un uso topico.
EP0853476B1 (en) Pharmaceutical preparation containing nimesulide for topical use
US11925621B2 (en) Medicinal preparation for external use
MXPA99005262A (en) Treatment of equine laminitis
RU2530644C2 (ru) Противоугревая фармацевтическая композиция и способ ее получения
ES2441917B1 (es) Composición farmacéutica para uso en inflamación y dolor
ES2289897B1 (es) Composicion para administracion transdermica de agentes fisiologicamente activos.
JP6084579B2 (ja) タクロリムスを含有する水中油型クリーム状組成物
KR100212969B1 (ko) 진통소염 외용 액제
WO2021232123A1 (pt) Plataforma para mascaramento de sabor
WO2005079855A1 (es) Composicion promotora de penetracion a base de esteres de acidos grasos de sacarosa